AbbVie (ABBV) will acquire Gilgamesh Pharmaceuticals' investigational depression drug for up to $1.2
PREMIUM
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Upgrade
Already have a subscription? Sign in
AbbVie to Buy Experimental Depression Drug From Gilgamesh For up to $1.2 Billion
Published 2 months ago
Aug 25, 2025 at 5:31 PM
Positive
Auto